Axsome Therapeutics Inc
NASDAQ:AXSM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
65.72
100.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Axsome Therapeutics Inc
Axsome Therapeutics Inc
Accrued Liabilities
Axsome Therapeutics Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Axsome Therapeutics Inc
NASDAQ:AXSM
|
Accrued Liabilities
$122m
|
CAGR 3-Years
121%
|
CAGR 5-Years
71%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Accrued Liabilities
$33.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accrued Liabilities
$13.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
16%
|
CAGR 10-Years
15%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Accrued Liabilities
$2.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Accrued Liabilities
$15.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Accrued Liabilities
$14.1B
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
18%
|
|
Axsome Therapeutics Inc
Glance View
Axsome Therapeutics Inc. emerged as a dynamic player in the biopharmaceutical arena, driven by a resolute commitment to alleviate the burdensome effects of central nervous system (CNS) disorders. Founded with a vision to fill critical treatment gaps in neurologically influenced conditions, Axsome leverages innovative drug discovery and development to address medical needs that have long been underserved. The company focuses intently on conditions such as depression, migraine, narcolepsy, and Alzheimer's disease-related agitation, channeling resources into a streamlined pipeline that seeks to fast-track the development and commercialization of life-changing therapies. Operating at the intersection of cutting-edge science and patient-centric healthcare, Axsome generates revenue through the successful approval and marketing of its proprietary pharmaceutical products. The company's business model hinges on advancing its clinical candidates through rigorous trials, eventually gaining the necessary regulatory endorsements to bring them to market. By holding the intellectual property rights for these novel drugs, Axsome enjoys the advantages of exclusivity in the marketplace, which allows it to negotiate favorable pricing and reimbursement terms. This strategic approach not only positions Axsome as a potentially transformative force within the pharmaceutical industry but also underlines its commitment to producing viable, accessible treatments for those grappling with debilitating CNS disorders.
See Also
What is Axsome Therapeutics Inc's Accrued Liabilities?
Accrued Liabilities
122m
USD
Based on the financial report for Sep 30, 2024, Axsome Therapeutics Inc's Accrued Liabilities amounts to 122m USD.
What is Axsome Therapeutics Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
71%
Over the last year, the Accrued Liabilities growth was 55%. The average annual Accrued Liabilities growth rates for Axsome Therapeutics Inc have been 121% over the past three years , 71% over the past five years .
You don't have any saved screeners yet
